Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia

Israel Medical Association Journal

Volumn 7, Issue 2, 2005, Pages 78-81

  Aizen, Eraim ^a   Kagan, Genady ^a   Assy, Bedia ^a   Lobel, Ranit ^a   Bershadsky, Yakov ^b   Gilhar, Amos ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Hemdat Avot Long Term Care Facility   (Israel)

Author keywords

Alzheimer disease; Atherosclerosis; Dementia; Natural killer; Non steroidal anti inflammatory drugs

Indexed keywords

ANTIINFLAMMATORY AGENT; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GROUPS BY AGE; HUMAN; HUMAN CELL; MALE; MULTIINFARCT DEMENTIA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; OPEN STUDY; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CEREBRAL INFARCTION; DEMENTIA, VASCULAR; DISEASE PROGRESSION; FEMALE; HUMANS; IBUPROFEN; KILLER CELLS, NATURAL; LACTONES; MALE; PROSPECTIVE STUDIES; SULFONES;

EID: 13844306486     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rogers J, Webster S, Lue LF, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996;17:861-6.
2. London JA, Biegel D, Pachter JS. Neurocytopathic effects of beta-amyloid-stimulated monocytes: a potential mechanism for central nervous system damage in Alzheimer disease. Proc Natl Acad Sci USA 1996;93:4147-52.
3. Pasinetti GM. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging 1996;17:707-16.
4. McGeer PL, Itagaki S, Tago H, et al. Reactive microglia in patients with senile dementia of the Alzheimer's type are positive for histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987;79:195-200.
5. Oda T, Lehrer-Graiwer J, Finch CE, et al. Complement and β-amyloid (aβ) neurotoxicity in vitro: a model for Alzheimer disease. Alzheimer Res 1995;1:29-34.
6. Bas A, Rutenbery A, Nofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.
7. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
8. Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
9. Solerte SB, Cravello L, Ferrari E, et al. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann N Y Acad Sci 2000;917:331-40.
10. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-91.
11. Curtiss LK, Kubo N, Schiller NK, et al. Participation of innate and acquired immunity in atherosclerosis. Immunol Res 2000;21:167-76.
12. Bruunsgaard H, Pedersen AN, Schroll M, et al. Decreased natural killer cell activity is associated with atherosclerosis in elderly humans. Exp Gerontol 2001;37:127-36.
13. Weyand CM, Goronzy JJ, Liuzzo G, et al. T-cell immunity in acute coronary syndromes. Mayo Clin Proc 2001;76:1011-20.
14. The Diagnostic and Statistical Manual of Disorders. Fourth edn. American Psychiatric Association Diagnostic and Statistical Manual. Washington DC: APA Press, 1994.
15. Morimoto C, Reinherz EL, Borel Y, et al. Direct demonstration of the human suppressor inducer subset by anti-T cell antibodies. J Immunol 1983;130:157.
16. Kalish R, Morimoto C, Schlossman SF. Generation of CD8 (T8) cytotoxic cells has a preferential requirement for CD4+2H4- inducer cells. Cell Immunol 1988;111:379-89.
17. Reinherz EL, Kung PC, Goldstein G, et al. Separation of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci USA 1979;76:4061.
18. Droller MJ, Schneider MU, Perlmann R A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol 1978;39:165-77.
19. Goto T, Herberman RB, Maluish A, et al. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol 1983;130:1350-5.
20. Vane JR. Introduction: mechanism of action of NSAIDs. Br J Rheumatol 1996;35(Suppl 1):1-3.
21. Borrego F, Alonso MC, Galiani MD, et al. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 1999;34:253-65.
22. Eikelenboom P, Rozemuller AJM, Hoozemans JJM, et al. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis Assoc Disord 2000; 14(Suppl):S54-61.
23. Akiyama H, Arai T, Kondo H, et al. Cell mediators of inflammation in the Alzheimer's disease brain. Alzheimer Dis Assoc Disord 2000;14(Suppl):S47-53.
24. Vermeer SE, Prins ND, Den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-22.
25. Henon H, Durieu I, Guerouaou D, et al. Poststroke dementia: incidence and relationship to poststroke cognitive decline. Neurology 2001:57: 1216-22.